Get the Stockscreener App
11.67
2.18%
-0.26
After Hours:
11.90
0.23
+1.97%
Contineum Therapeutics Inc stock is traded at $11.67, with a volume of 71,709.
It is down -2.18% in the last 24 hours and down -5.54% over the past month.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
See More
Previous Close:
$11.93
Open:
$12
24h Volume:
71,709
Relative Volume:
0.29
Market Cap:
$252.37M
Revenue:
-
Net Income/Loss:
$-35.46M
P/E Ratio:
-27.67
EPS:
-0.4218
Net Cash Flow:
$-34.00M
1W Performance:
+2.46%
1M Performance:
-5.54%
6M Performance:
+192.48%
1Y Performance:
-29.10%
1-Day Range:
$11.56
$12.00
1-Week Range:
$11.28
$12.80
52-Week Range:
$3.35
$20.24
Contineum Therapeutics Inc Stock (CTNM) Company Profile
Name
Contineum Therapeutics Inc
Sector
Industry
Phone
(858) 333-5280
Address
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
Compare CTNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
11.67 | 333.14M | 0 | -35.46M | -34.00M | -0.4218 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-25 | Initiated | Leerink Partners | Outperform |
| Jun-20-25 | Initiated | William Blair | Outperform |
| Oct-22-24 | Initiated | Robert W. Baird | Outperform |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Apr-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-30-24 | Initiated | Stifel | Buy |
View All
Contineum Therapeutics Inc Stock (CTNM) Latest News
Can Contineum Therapeutics Inc. stock outperform in 2025 bull marketJuly 2025 Market Mood & Target Return Focused Picks - newser.com
How Contineum Therapeutics Inc. stock compares to growth peers2025 Top Decliners & Weekly Top Gainers Alerts - newser.com
Is it time to cut losses on Contineum Therapeutics Inc.Dividend Hike & AI Forecast for Swing Trade Picks - newser.com
RBC Capital Maintains Contineum Therapeutics(CTNM.US) With Buy Rating, Maintains Target Price $25 - 富途牛牛
Contineum Therapeutics stock rating reiterated by RBC on MS drug potential - Investing.com
Will Contineum Therapeutics Inc. stock split attract more investorsJuly 2025 Breakouts & Weekly Watchlist of Top Performers - newser.com
CTNM Eyes Q4 Data From PIPE-307 MS Trial; PIPE-791 Advances Toward IPF Proof-Of-Concept - RTTNews
Custom watchlist performance reports with Contineum Therapeutics Inc.July 2025 News Drivers & Weekly Chart Analysis and Trade Guides - newser.com
Is Contineum Therapeutics Inc. stock bottoming outTrade Exit Summary & Community Consensus Trade Signals - newser.com
What MACD signals say about Contineum Therapeutics Inc.2025 Risk Factors & Reliable Momentum Entry Alerts - newser.com
Critical Comparison: Contineum Therapeutics (NASDAQ:CTNM) & Kyverna Therapeutics (NASDAQ:KYTX) - Defense World
We're Not Very Worried About Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Rate - simplywall.st
Real time scanner hits for Contineum Therapeutics Inc. explainedWeekly Trade Analysis & Capital Efficiency Focused Ideas - newser.com
Reversal indicators forming on Contineum Therapeutics Inc. stockJuly 2025 Big Picture & Stepwise Entry and Exit Trade Signals - newser.com
Multi asset correlation models including Contineum Therapeutics Inc.Day Trade & Stepwise Swing Trade Plans - newser.com
Published on: 2025-10-05 04:13:38 - newser.com
Smart tools for monitoring Contineum Therapeutics Inc.’s price action2025 Bull vs Bear & AI Powered Buy and Sell Recommendations - newser.com
Candlestick signals on Contineum Therapeutics Inc. stock today2025 Market Sentiment & Daily Price Action Insights - newser.com
Contineum Therapeutics discovers new LPAR1 antagonists - BioWorld MedTech
Published on: 2025-10-01 09:30:13 - newser.com
Published on: 2025-10-01 09:12:08 - newser.com
Published on: 2025-09-30 20:32:54 - newser.com
Here's Why We're Not Too Worried About Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Situation - Yahoo Finance
Contineum Therapeutics, Inc. $CTNM Stock Position Reduced by Goldman Sachs Group Inc. - Defense World
Published on: 2025-09-30 00:03:50 - newser.com
What is Leerink Partnrs’ Estimate for CTNM Q3 Earnings? - Defense World
What is Leerink Partnrs' Estimate for CTNM Q3 Earnings? - MarketBeat
Published on: 2025-09-29 00:01:35 - newser.com
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Relative strength of Contineum Therapeutics Inc. in sector analysisPortfolio Performance Summary & Weekly High Potential Stock Alerts - newser.com
Contineum Therapeutics (NASDAQ:CTNM) Stock Rating Upgraded by Leerink Partnrs - Defense World
Contineum Therapeutics (NASDAQ:CTNM) Now Covered by Leerink Partners - Defense World
Custom strategy builders for tracking Contineum Therapeutics Inc.2025 Market Outlook & Long-Term Safe Return Strategies - newser.com
Contineum Therapeutics (NASDAQ:CTNM) Upgraded to Strong-Buy at Leerink Partnrs - MarketBeat
Leerink Partners initiates Contineum Therapeutics stock with Outperform rating - Investing.com India
CTNM Coverage Initiated by Leerink Partners with Outperform Rating | CTNM Stock News - GuruFocus
Leerink Partners initiates Contineum Therapeutics stock with Outperform rating By Investing.com - Investing.com Nigeria
Contineum Therapeutics (NASDAQ:CTNM) Coverage Initiated at Leerink Partners - MarketBeat
Leerink Partners Initiates Coverage of Contineum Therapeutics (CTNM) with Outperform Recommendation - Nasdaq
Leerink Partners Initiates Contineum Therapeutics(CTNM.US) With Buy Rating, Announces Target Price $20 - 富途牛牛
Leerink Partners Initiates Contineum Therapeutics at Outperform With $20 Price Target - MarketScreener
Leerink bullish on Contineum, initiates with an Outperform - TipRanks
Published on: 2025-09-24 03:07:05 - newser.com
Will Contineum Therapeutics Inc. outperform the marketGold Moves & Real-Time Chart Breakout Alerts - newser.com
Visual analytics tools that track Contineum Therapeutics Inc. performanceTrade Analysis Report & Proven Capital Preservation Methods - newser.com
Published on: 2025-09-22 10:50:04 - newser.com
Can momentum traders help lift Contineum Therapeutics Inc.Earnings Risk Report & Fast Gain Stock Tips - newser.com
Can technical indicators confirm Contineum Therapeutics Inc.’s reversalWeekly Volume Report & AI Driven Price Forecasts - newser.com
Contineum Therapeutics Inc Stock (CTNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.15%
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):